MNL Pharmaceuticals

MNLpharma (‘MNL’) is a private UK drug discovery and development company focused on the exploitation of imino sugar therapeutics for the prevention and treatment of disease. The company’s in-house programmes focus on cancer, and infectious diseases. MNLpharma has discovery and development programmes in the areas of immunomodulation and direct acting antivirals with a number of compounds showing promise against several key viral pathogens where effective treatments are currently lacking.

MNLpharma’s lead compound (MNLP462a) is an imino sugar immunomodulator which has demonstrated impressive protective and therapeutic effects in in vivo cancer models. As a broad spectrum immunotherapeutic MNLP462a is anticipated to be developed for use in a wide range of diseases including infection and as such has great commercial value and potential. This candidate will enter the clinic in 2006.

In addition to imino sugars, the company has a unique chemistry platform of pure, novel, drug-like natural compounds called Phytopure™. This collection is being exploited in a limited number of highly targeted collaborations. Whilst its own imino sugar therapeutics are being developed in-house, MNLpharma seeks to exploit Phytopure™ through a limited number of alliances with companies that are leaders in specific fields.